About Totus Medicines
Totus Medicines is a company based in Cambridge (United States) founded in 2019 by Neil Dhawan.. Totus Medicines has raised $106 million across 2 funding rounds from investors including DCVC, Northpond Ventures and Camford. The company has 23 employees as of December 31, 2021. Totus Medicines operates in a competitive market with competitors including Zymeworks, Xilio Therapeutics, Harbour BioMed, Ambrx and Lassen Therapeutics, among others.
- Headquarter Cambridge, United States
- Employees 23 as on 31 Dec, 2021
- Founders Neil Dhawan
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
$155.44 K (USD)-12as on Dec 31, 2022
-
Net Profit
$17.03 K (USD)-70as on Dec 31, 2022
-
EBITDA
-
Total Equity Funding
$106 M (USD)
in 2 rounds
-
Latest Funding Round
$66 M (USD), Series B
Dec 15, 2023
-
Investors
DCVC
& 5 more
-
Employee Count
23
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of Totus Medicines
Totus Medicines has successfully raised a total of $106M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $66 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $66.0M
-
First Round
First Round
(09 Dec 2021)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2023 | Amount | Series B - Totus Medicines | Valuation | DCVC | |
| Dec, 2021 | Amount | Series A - Totus Medicines | Valuation | DCVC , Northpond Ventures |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Totus Medicines
Totus Medicines has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include DCVC, Northpond Ventures and Camford. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on multiple sectors
|
Founded Year | Domain | Location | |
|
Venture capital firm investing in life sciences & tech sectors
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Totus Medicines
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Totus Medicines
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Totus Medicines Comparisons
Competitors of Totus Medicines
Totus Medicines operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Zymeworks, Xilio Therapeutics, Harbour BioMed, Ambrx and Lassen Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Bi-specific antibodies and antibody-drug conjugates are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Tumor-selective immunotherapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Antibody therapeutics are developed for immunology and oncology diseases.
|
|
| domain | founded_year | HQ Location |
Antibody-drug conjugates are developed for cancers and metabolic disorders.
|
|
| domain | founded_year | HQ Location |
Biotherapeutics targeting cancer via interleukin-11 are developed.
|
|
| domain | founded_year | HQ Location |
Novel immuno-oncology therapeutics are acquired and developed for clinical advancement.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Totus Medicines
Frequently Asked Questions about Totus Medicines
When was Totus Medicines founded?
Totus Medicines was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Where is Totus Medicines located?
Totus Medicines is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Who is the current CEO of Totus Medicines?
Neil Dhawan is the current CEO of Totus Medicines. They have also founded this company.
Is Totus Medicines a funded company?
Totus Medicines is a funded company, having raised a total of $106M across 2 funding rounds to date. The company's 1st funding round was a Series A of $40M, raised on Dec 09, 2021.
How many employees does Totus Medicines have?
As of Dec 31, 2021, the latest employee count at Totus Medicines is 23.
What is the annual revenue of Totus Medicines?
Annual revenue of Totus Medicines is $155.44K as on Dec 31, 2022.
What does Totus Medicines do?
Provider of genome-scale drug discovery platform to treat multiple diseases. The company combines proprietary cellular analysis and machine learning technology to translate the revolution in genomic sequencing to create covalent therapeutics to treat cancer, heart disease, neurodegeneration, and more. The companys lead candidate TOS-358 is a potent inhibitor of PI3Kα for the treatment of colorectal, lung, breast, ovarian, esophageal, head and neck cancer.
Who are the top competitors of Totus Medicines?
Totus Medicines's top competitors include Xilio Therapeutics, Ambrx and Harbour BioMed.
Who are Totus Medicines's investors?
Totus Medicines has 6 investors. Key investors include DCVC, Northpond Ventures, Camford, University of Minnesota Twin Cities, and Camford Capital.